☰

John P. Fruehauf

Affiliations: 
Biomedical Engineering - Ph.D. University of California, Irvine, Irvine, CA 
Area:
Biomedical Engineering
Google:
"John Fruehauf"
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
John P. Sinek grad student 2005 UC Irvine
Valerie Trapp grad student 2009 UC Irvine
Basmina Parmakhtiar grad student 2012 UC Irvine

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhuang E, Jakowatz JG, Yamamoto M, et al. (2020) Open label, phase II study of axitinib, a selective inhibitor of vascular endothelial growth factor receptors, in patients with stage III malignant melanoma. Journal of Clinical Oncology. 38: e22062-e22062
Fruehauf JP, Gomez DC, Spitalny L, et al. (2020) Abstract 4098: Topotecan-mediated inhibition of HIF1α/ARV7 heterodimers in 22RV1 prostate cancer cells prevents ARV7 nuclear entry, reversing enzalutamide resistance Cancer Research. 80: 4098-4098
Parmakhtiar B, Burger RA, Kim JH, et al. (2019) HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Molecular Cancer Research : McR
Fruehauf JP, El-Masry M, Osann K, et al. (2018) Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology
Longoria T, Sill M, Monk B, et al. (2018) GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study Gynecologic Oncology. 149: 37-38
Fruehauf JP, Farrokh N, Sarkissian S, et al. (2017) Abstract A37: Blockade of ARV7:HIF1α; heterodimers after toptoecan reverses enzalutamide resistance in 22Rv1 cells Cancer Research. 77
Sarkissian S, Fruehauf JP. (2016) Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series. Journal of Clinical Oncology. 34: e22528-e22528
Fruehauf JP, Farrokhian N, Sarkissian S, et al. (2016) Blockade of ARV7:HIF1α heterodimers after topotecan reverses enzalutamide resistance in 22Rv1 cells. Journal of Clinical Oncology. 34: e16594-e16594
Tortorici MA, Cohen EE, Pithavala YK, et al. (2014) Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemotherapy and Pharmacology. 74: 1279-89
Fruehauf JP, Alger B, Jakowatz JG, et al. (2014) A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma. Journal of Clinical Oncology. 32: 9036-9036
See more...